BioVie to Present Phase 2 Long COVID Data at NIH Workshop
BioVie will present Phase 2 ADDRESS-LC data on bezisterim at an NIH RECOVER-TLC workshop. The overall intent-to-treat population did not achieve statistical significance; the company cites subgroup benefits and a safety profile similar to placebo.